Supplements

Mucuna Pruriens

Updated · 31 sources · Editorial policy

Mucuna pruriens, also called velvet bean or cowhage, is a tropical legume whose seeds are one of the richest natural sources of levodopa (L-DOPA). Levodopa is the dopamine precursor that has been the standard drug treatment for Parkinson’s disease for decades. Mucuna has a long history in Ayurvedic medicine and is sold today as a dietary supplement, often marketed for libido, mood, “dopamine support,” testosterone and lower prolactin.

The single most important fact about Mucuna is that it is a levodopa product. Small trials in Parkinson’s disease show that the seed powder works like levodopa, with levodopa’s side effects and drug interactions. The fertility and hormone claims rest mostly on uncontrolled studies from one research group. No regulator has approved Mucuna for any medical use, and tested supplements often do not contain the amount of levodopa on the label.

This page summarizes what the clinical trials, the levodopa drug label and supplement analyses report. It is for education only and is not medical advice.

Property Detail
What it is Seed of a tropical legume (family Fabaceae)
Main active compound Levodopa (L-DOPA), the precursor of dopamine
Levodopa content ≈0.6–6.4% of dry seed weight across 56 seed accessions; extracts are sold standardized to higher percentages
Route Oral: seed powder, extracts, capsules
Doses used in trials Parkinson’s: single doses of 15–30 g powder; ≈37 g/day powder in a 12-month trial. Male infertility: 5 g/day seed powder for 3 months
Half-life Levodopa ≈50 min without carbidopa (levodopa label); Mucuna and a levodopa tablet had similar half-lives in a 2025 crossover trial
US status Sold as a dietary supplement; not approved by FDA or EMA for any condition
WADA status Not named on the 2026 Prohibited List

What it is

Mucuna pruriens is a climbing legume that grows across tropical regions. Its seeds contain levodopa, chemically (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid, formula C₉H₁₁NO₄, molecular weight 197.19 g/mol (PubChem). This is the same molecule as pharmaceutical levodopa.

The levodopa content varies a lot between plants and preparations:

Source Levodopa content
56 accessions of four Mucuna varieties (Pulikkalpura et al., Sci Rep 2015) 0.58–6.42% of dry weight
25 seed samples from Africa, Latin America and Asia (Cassani et al., J Neurol Sci 2016) Median 5.29% in dried seeds; 5.3% in roasted powder
Bolivian black seeds used in a 2017 trial (Cilia et al., Neurology 2017) 5.7%
Ghanaian seeds used in a 12-month trial (Cilia et al., J Parkinsons Dis 2026) 6.3%

Preparation matters as well. In the Cassani analysis, boiling reduced the levodopa content by up to 70%.

The name “cowhage” refers to the stinging hairs on the seed pods. Their active itch-causing component is a protease called mucunain, which acts on protease-activated receptors in the skin (Reddy et al., J Neurosci 2008). Cowhage spicules are used in research as a model of itch that does not depend on histamine.

How it works in the body

Levodopa crosses into the brain and is converted to dopamine there. Dopamine is the brain chemical that is lost in Parkinson’s disease, and it also acts on the pituitary to restrain prolactin release.

The key difference from prescription levodopa is the absence of a decarboxylase inhibitor. Pharmaceutical levodopa is combined with carbidopa or benserazide, which block the conversion of levodopa to dopamine outside the brain. According to the carbidopa-levodopa label (Sinemet, DailyMed):

  • carbidopa reduces the amount of levodopa needed for the same effect by about 75%;
  • the plasma half-life of levodopa is about 50 minutes without carbidopa and about 1.5 hours with it;
  • adding carbidopa reduces the nausea and vomiting caused by dopamine formed outside the brain.

Mucuna supplies levodopa without carbidopa, so more of it is converted before it reaches the brain. In a pharmacokinetic study in four patients, Mucuna extract at a levodopa dose similar to levodopa plus a decarboxylase inhibitor gave less clinical benefit, with a 3.5-fold lower median exposure (area under the curve, AUC) (Cassani et al., J Neurol Sci 2016). The authors concluded that Mucuna needs at least 3.5 times the levodopa dose of a standard combined tablet to match it.

When the dose is high enough, Mucuna can produce higher levodopa levels than a standard tablet. In a 2025 crossover trial, 30 g of Mucuna powder gave a geometric mean AUC of 12,425 vs 7,982 ng·h/mL for levodopa/benserazide 200/50 mg, a ratio of 155.7% (90% CI 134.6–180.0). Time to peak and half-life were similar for the two (Boonmongkol et al., J Neural Transm 2025).

Regulatory status

  • United States. Mucuna is sold as a dietary supplement. It is not approved or registered for Parkinson’s disease by the FDA or the EMA, and it is not an authorized alternative to levodopa medicines (Cilia and Katzenschlager, J Parkinsons Dis 2026).
  • Italy. Mucuna extract is not allowed in dietary supplements, according to researchers at Italy’s National Institute of Health (Istituto Superiore di Sanità) (Aureli et al., Front Chem 2025).
  • Sport. Neither Mucuna nor levodopa is named on the WADA 2026 Prohibited List. Multi-ingredient products should be judged by their full label.

What the research shows

Parkinson’s disease

Parkinson’s disease is the only use with randomized human trials. A 2025 systematic review found 5 clinical trials comparing Mucuna with levodopa, with 108 participants in total. It rated one trial as high quality, one as having some concerns and three as low quality (Hammoud et al., Parkinsons Dis 2025). A further 12-month trial was published after that review.

Trial Design and n Comparison Main result
HP-200 Study Group, 1995 Open-label, 60 patients, 12 weeks No control; 7.5 g sachets of a Mucuna product UPDRS and Hoehn and Yahr stage improved; mean dose 6 ± 3 sachets; mainly mild gastrointestinal side effects
Katzenschlager et al., 2004 Double-blind, randomized crossover, 8 patients, single doses 15 g and 30 g Mucuna vs levodopa/carbidopa 200/50 mg 30 g: onset 34.6 vs 68.5 min; on time 21.9% (37 min) longer; peak levodopa 110% higher; no difference in dyskinesia
Cilia et al., 2017 Double-blind, randomized crossover, 18 patients, single doses, six arms including placebo Mucuna at 12.5 and 17.5 mg/kg levodopa vs levodopa/benserazide at 3.5 mg/kg Met all noninferiority outcomes; the high dose gave greater motor improvement, longer on time and fewer dyskinesias
Cilia et al., 2018 Randomized crossover, 14 patients, 16 weeks of daily use Mucuna powder vs levodopa/carbidopa 7 of 14 (50%) stopped Mucuna early (4 for gastrointestinal effects, 3 for worsening motor function); none stopped levodopa/carbidopa
Boonmongkol et al., 2025 Single-blind, randomized crossover, 12 patients (11 analyzed), single doses 30 g Mucuna vs levodopa/benserazide 200/50 mg On time without dyskinesia 232.2 vs 161.8 min (p = 0.01); nausea and dizziness more frequent with Mucuna
Cilia et al., 2026 Open-label randomized phase 2, 32 untreated patients in Ghana, 12 months Mucuna powder vs levodopa plus a decarboxylase inhibitor Similar quality of life, motor and non-motor outcomes; adverse events 56% vs 37.5% (p = 0.48); 12.5% stopped Mucuna

Three points stand out:

  • The doses are large. In the 12-month Ghana trial, the mean maintenance dose was 36.7 g/day of powder, estimated to supply 2.3 g/day of levodopa. The comparison group took a mean of 410 mg/day of levodopa with a decarboxylase inhibitor (Cilia et al., J Parkinsons Dis 2026).
  • Single-dose results looked better than daily use. Single doses were well tolerated, but half the patients in the 16-week daily trial could not stay on Mucuna. That trial switched patients from carbidopa-levodopa to levodopa alone fairly quickly, which the authors considered a likely cause.
  • The aim of this research is access, not superiority. The Bolivia and Ghana trials asked whether locally grown seeds could replace levodopa for patients who cannot afford it. The investigators recommend that Mucuna be used only within trials or neurologist-led protocols (Cilia and Katzenschlager, J Parkinsons Dis 2026).

Male infertility

The fertility studies come from one research group in Lucknow, India (King George’s Medical University, also listed as C.S.M. Medical University), with overlapping authors. Each enrolled infertile men, gave them Mucuna seed powder, and compared their values before and after treatment (3 months in the studies that state the duration). Healthy fertile men served as a reference group; in the 2010 study, the only one whose full text we could read, they did not receive Mucuna.

Study Infertile men Fertile reference men What was measured Reported result
Ahmad et al., Fertil Steril 2008 60 60 Semen profile, seminal lipids, fructose, vitamins A, C and E Higher sperm concentration and motility; motility not restored to normal in asthenozoospermic men
Shukla et al., Fertil Steril 2009 75 75 Testosterone, LH, FSH, prolactin, catecholamines Testosterone and LH rose; FSH and prolactin fell; sperm count and motility improved
Shukla et al., EBCAM 2010 60 (with psychological stress) 60 Anxiety score, cortisol, seminal antioxidants Cortisol and seminal lipid peroxides fell; sperm concentration +688% in oligozoospermic men
Gupta et al., J Pharm Biomed Anal 2011 180 50 Seminal plasma metabolites by NMR, hormones Metabolite profile and semen quality improved

In the 2010 study, the dose was 5 g/day of seed powder taken once daily with milk for 3 months (full text, PMC). A 2019 review of herbal products summarized the data as a rise in total testosterone of about 151 ng/dL and in sperm concentration of 83.3 million/mL with 5 g/day for 12 weeks in oligozoospermic men (Santos et al., J Ethnopharmacol 2019).

These results cannot be taken at face value because of how the studies were designed:

  • No placebo and no randomization. Every infertile man received Mucuna. Without an untreated or placebo group, the changes cannot be separated from regression to the mean (men recruited at a low point tend to measure higher later), lifestyle change or seasonal variation in semen.
  • No blinding. The investigators and participants knew who was treated.
  • Surrogate outcomes. The studies measured semen and blood markers, not pregnancies or live births.
  • One center, no independent replication. We found no randomized, placebo-controlled trial of Mucuna for male infertility from any other group.
  • Large effects from small changes. A +688% rise in sperm concentration starting from a very low baseline is the kind of result that most needs confirmation in a controlled trial.

Cilia and Katzenschlager’s 2026 review of the evidence concluded that human data for uses outside Parkinson’s disease, including male infertility, are lacking and that these uses remain speculative (J Parkinsons Dis 2026).

Prolactin, growth hormone and testosterone claims

Supplement marketing often presents Mucuna as a natural way to lower prolactin, raise growth hormone (GH) and raise testosterone. Each claim has a pharmacological basis in levodopa, but none has been shown for Mucuna in controlled trials in healthy men.

Claim Pharmacological basis Human evidence for Mucuna
Lowers prolactin Dopamine restrains prolactin release from the pituitary Small 1978 reports that Mucuna and L-DOPA countered drug-induced high prolactin (Vaidya et al., Neurol India 1978; Vaidya et al., Neurol India 1978); lower prolactin in the uncontrolled Shukla 2009 study
Raises growth hormone A single dose of L-DOPA stimulates GH release in humans (Boyd et al., NEJM 1970); this is the basis of the L-DOPA stimulation test used to diagnose GH deficiency No trial showing a sustained rise in GH, IGF-1 or muscle mass
Raises testosterone Proposed effect through LH Rises only in the uncontrolled infertility studies; no placebo-controlled trial in healthy or trained men

Two points put these claims in context:

  • A brief GH pulse is not a GH treatment. The L-DOPA stimulation test measures an acute response. It does not show that repeated doses raise 24-hour GH or IGF-1, or build muscle.
  • The one controlled training trial found nothing. In a randomized, double-blind trial in 42 resistance-trained men, a nightly ZMA-type product that also contained a Mucuna extract standardized to 50 mg of L-DOPA did not change anabolic or catabolic hormones, body composition or strength over 8 weeks compared with placebo (Wilborn et al., JISSN 2004). The product had several ingredients, so it cannot isolate Mucuna, but it gives no support for a hormonal effect at supplement-label doses.

For high prolactin, the drugs with regulatory approval and controlled trial data are the dopamine agonists cabergoline and bromocriptine. Pramipexole is a dopamine agonist approved for Parkinson’s disease and restless legs syndrome. Unlike Mucuna, these act directly on dopamine receptors and are sold at a defined, verified dose. Other botanicals marketed for libido or testosterone, such as maca, tongkat ali and ashwagandha, and the amino acid D-aspartic acid, have their own pages.

Side effects and risks

Because Mucuna’s active ingredient is levodopa, the levodopa drug label is the best available guide to its risks. The label below covers carbidopa-levodopa. Mucuna lacks carbidopa, so more levodopa is converted to dopamine outside the brain, which raises the risk of gastrointestinal and cardiovascular side effects (Cilia and Katzenschlager, J Parkinsons Dis 2026).

Levodopa side effects

The carbidopa-levodopa label lists the most common adverse reactions as dyskinesias (involuntary movements) and nausea (Sinemet, DailyMed). Its warnings also include:

  • Orthostatic hypotension (a drop in blood pressure on standing), fainting and heart rhythm irregularities;
  • Hallucinations and psychosis, including paranoia, confusion and agitation; people with a major psychotic disorder should generally not be treated with it;
  • Impulse control problems, such as urges to gamble, spend, binge eat or increased sexual urges;
  • Sudden sleep onset during daily activities, including while driving;
  • A neuroleptic malignant syndrome-like reaction (fever, rigidity, confusion) when levodopa is stopped or cut abruptly;
  • Melanoma: people with Parkinson’s disease have a 2- to about 6-fold higher melanoma risk, and the label advises regular skin checks;
  • Dark saliva, urine or sweat, which is harmless.

In the Mucuna trials, the most common problems were gastrointestinal. Nausea, dizziness and somnolence were reported most often, mainly early in treatment or at higher doses (Cilia and Katzenschlager, J Parkinsons Dis 2026). In the 12-month Ghana trial, no serious adverse events occurred in either arm, and laboratory tests showed no liver, kidney or blood toxicity (Cilia et al., J Parkinsons Dis 2026).

Overuse and dopamine dysregulation

Mucuna’s “natural” image can encourage unsupervised dose escalation. Published cases include:

  • a woman with Parkinson’s disease who developed dopamine dysregulation syndrome (compulsive overuse of dopamine medicine). She took Mucuna capsules about every 3 hours on top of her prescribed drugs, had repeated episodes of psychosis, agitation and dyskinesia, and was admitted after taking about 100 capsules over 2 days (Sohutskay et al., J Mov Disord 2024);
  • a patient who used Mucuna exclusively for about two decades and still developed severe motor fluctuations and dyskinesias requiring deep brain stimulation (Margolesky et al., Parkinsonism Relat Disord 2020).

Raw seeds and poisoning

Improperly prepared seeds can cause poisoning:

Drug interactions

The carbidopa-levodopa label lists these interactions (Sinemet, DailyMed):

Drug or group Interaction
Nonselective MAO inhibitors Contraindicated; must be stopped at least 2 weeks before starting levodopa
Selegiline (MAO-B inhibitor) May cause severe orthostatic hypotension
Blood pressure medicines Symptomatic postural hypotension; dose adjustment may be needed
Tricyclic antidepressants Rare reports of hypertension and dyskinesia
Dopamine D2 blockers (antipsychotics such as phenothiazines, butyrophenones, risperidone; metoclopramide) and isoniazid Reduce the effect of levodopa
Phenytoin and papaverine Reported to reverse levodopa’s benefit
Reserpine, tetrabenazine Not recommended together
Iron salts, including iron in multivitamins Bind levodopa and reduce absorption
Pyridoxine (vitamin B6), 10–25 mg Can reverse the effect of levodopa given without carbidopa

The last point is especially relevant to Mucuna. The label notes that carbidopa blocks the vitamin B6 effect, but Mucuna contains no carbidopa. Vitamin B6 is a common ingredient in multivitamins and “testosterone” or sleep formulas.

Combining Mucuna with prescription Parkinson’s drugs, dopamine agonists such as pramipexole or cabergoline, or MAO-B and COMT inhibitors has not been studied. There is no guidance on how to adjust these drugs when Mucuna is added (Cilia and Katzenschlager, J Parkinsons Dis 2026).

Who should not use it

Based on the levodopa label, the main contraindications and cautions are:

  • current or recent (within 2 weeks) use of a nonselective MAO inhibitor;
  • narrow-angle glaucoma;
  • a major psychotic disorder;
  • severe heart or lung disease, asthma, or kidney, liver or endocrine disease;
  • a history of heart attack with residual rhythm problems, or of peptic ulcer (higher risk of upper gastrointestinal bleeding);
  • pregnancy and breastfeeding: levodopa crosses the placenta and passes into breast milk, and combined carbidopa-levodopa caused malformations in rabbits.

Quality and contamination

Mucuna supplements vary widely in how much levodopa they contain, and labels are often wrong:

Analysis Products Finding
Soumyanath et al., J Altern Complement Med 2018 6 commercial products, US Levodopa ranged from 6% to 141% of the label claim; none fell within the 90–110% pharmacopeial range; maximum daily levodopa delivered 14.4–720 mg
Cohen et al., JAMA Neurol 2022 20 products from the NIH Dietary Supplement Label Database Large differences between labeled and measured levodopa (as summarized by Cilia and Katzenschlager 2026)
Aureli et al., Front Chem 2025 4 high-percentage L-DOPA products bought online Levodopa present in all; some overdosed and others underdosed relative to the label; no undeclared drugs found
Phillips et al., Amino Acids 2026 5 Mucuna preparations Levodopa was 66.2–82.7% of the manufacturers’ stated values

The upper end of the 2018 range, 720 mg/day, is within the range of prescription levodopa therapy. Some products are labeled as standardized to 15% or 50% levodopa, far above the 4–6% typical of the seeds, and measured content in such products has differed from the label several-fold (Cilia and Katzenschlager, J Parkinsons Dis 2026). A buyer cannot tell from the label how much levodopa a product delivers, and the same product may vary between batches.

Key takeaways

  • Mucuna is a levodopa product. Its seeds usually contain about 4–6% levodopa, the same molecule as the Parkinson’s drug, but without the carbidopa that pharmaceutical levodopa includes.
  • It works in Parkinson’s disease at large doses. Small randomized trials found that single doses of 15–30 g, and about 37 g/day long term, matched standard levodopa, but half of patients in one 16-week trial stopped Mucuna early.
  • The fertility data are weak. The infertility studies come from one group, had no placebo or randomization, and measured semen markers rather than pregnancies.
  • Hormone claims are not shown in healthy men. L-DOPA briefly raises GH and can lower prolactin, but no placebo-controlled trial shows that Mucuna raises testosterone, GH or muscle mass in healthy or trained men.
  • It carries levodopa’s risks. These include nausea, low blood pressure, dyskinesia, psychosis, impulse control problems and a dangerous interaction with nonselective MAO inhibitors.
  • Labels are unreliable. Tested products contained 6–141% of their labeled levodopa.

Sources

  1. National Center for Biotechnology Information. Levodopa, PubChem CID 6047. PubChem.
  2. Organon. Sinemet (carbidopa and levodopa) tablets, prescribing information. DailyMed.
  3. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep. 2015;5:11078. PubMed.
  4. Cassani E, Cilia R, Laguna J, et al. Mucuna pruriens for Parkinson’s disease: low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci. 2016;365:175–180. PubMed.
  5. Reddy VB, Iuga AO, Shimada SG, LaMotte RH, Lerner EA. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci. 2008;28(17):4331–4335. PubMed.
  6. HP-200 in Parkinson’s Disease Study Group. An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. J Altern Complement Med. 1995;1(3):249–255. PubMed.
  7. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672–1677. PubMed.
  8. Cilia R, Laguna J, Cassani E, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology. 2017;89(5):432–438. PubMed.
  9. Cilia R, Laguna J, Cassani E, et al. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018;49:60–66. PubMed.
  10. Boonmongkol T, Phokaewvarangkul O, Vimolmangkang S, et al. Comparative efficacy of Mucuna pruriens and conventional levodopa in Parkinson’s disease: a randomized controlled trial on pharmacokinetics and clinical perspectives from Asia. J Neural Transm (Vienna). 2025;132(11):1673–1683. PubMed.
  11. Cilia R, Cham M, Obese V, et al. Mucuna pruriens in untreated Parkinson’s disease in sub-Saharan Africa: a 12-month, multicenter, randomized, controlled trial. J Parkinsons Dis. 2026;16(1):99–109. PubMed.
  12. Hammoud F, Ismail A, Zaher R, et al. Mucuna pruriens treatment for Parkinson disease: a systematic review of clinical trials. Parkinsons Dis. 2025;2025:1319419. PubMed.
  13. Cilia R, Katzenschlager R. “To Bean or Not to Bean”: therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens. J Parkinsons Dis. 2026;16(4):788–794. PubMed.
  14. Ahmad MK, Mahdi AA, Shukla KK, et al. Effect of Mucuna pruriens on semen profile and biochemical parameters in seminal plasma of infertile men. Fertil Steril. 2008;90(3):627–635. PubMed.
  15. Shukla KK, Mahdi AA, Ahmad MK, et al. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertil Steril. 2009;92(6):1934–1940. PubMed.
  16. Shukla KK, Mahdi AA, Ahmad MK, et al. Mucuna pruriens reduces stress and improves the quality of semen in infertile men. Evid Based Complement Alternat Med. 2010;7(1):137–144. PubMed; PMC.
  17. Gupta A, Mahdi AA, Ahmad MK, et al. A proton NMR study of the effect of Mucuna pruriens on seminal plasma metabolites of infertile males. J Pharm Biomed Anal. 2011;55(5):1060–1066. PubMed.
  18. Santos HO, Howell S, Teixeira FJ. Beyond tribulus (Tribulus terrestris L.): the effects of phytotherapics on testosterone, sperm and prostate parameters. J Ethnopharmacol. 2019;235:392–405. PubMed.
  19. Vaidya RA, Sheth AR, Aloorkar SD, et al. The inhibitory effect of the cowhage plant-Mucuna pruriens-and L-dopa on chlorpromazine-induced hyperprolactinaemia in man. Neurol India. 1978;26(4):177–178. PubMed.
  20. Vaidya RA, Aloorkar SD, Sheth AR, Pandya SK. Activity of bromoergocryptine, Mucuna pruriens and L-dopa in the control of hyperprolactinaemia. Neurol India. 1978;26(4):179–182. PubMed.
  21. Boyd AE 3rd, Lebovitz HE, Pfeiffer JB. Stimulation of human-growth-hormone secretion by L-dopa. N Engl J Med. 1970;283(26):1425–1429. PubMed.
  22. Wilborn CD, Kerksick CM, Campbell BI, et al. Effects of zinc magnesium aspartate (ZMA) supplementation on training adaptations and markers of anabolism and catabolism. J Int Soc Sports Nutr. 2004;1(2):12–20. PubMed.
  23. Sohutskay DO, Suen RM, Ali F, Rosenman DJ. Dopamine dysregulation syndrome presenting as overuse of Mucuna pruriens levodopa supplement. J Mov Disord. 2024;17(3):357–359. PubMed.
  24. Margolesky J, Shpiner DS, Moore H, et al. From Mucuna pruriens to deep brain stimulation: a two-decade case history. Parkinsonism Relat Disord. 2020;77:26–27. PubMed.
  25. Infante ME, Perez AM, Simao MR, et al. Outbreak of acute toxic psychosis attributed to Mucuna pruriens. Lancet. 1990;336(8723):1129. PubMed.
  26. Maillot A, Schmitt C, Marteau A. Poisoning after ingestion of Mucuna pruriens seeds on Reunion Island. Wilderness Environ Med. 2022;33(1):122–124. PubMed.
  27. Soumyanath A, Denne T, Hiller A, et al. Analysis of levodopa content in commercial Mucuna pruriens products using high-performance liquid chromatography with fluorescence detection. J Altern Complement Med. 2018;24(2):182–186. PubMed.
  28. Cohen PA, Avula B, Katragunta K, Khan I. Levodopa content of Mucuna pruriens supplements in the NIH Dietary Supplement Label Database. JAMA Neurol. 2022;79(10):1085–1086. PubMed.
  29. Aureli F, Gaudiano MC, Raimondo M, et al. Quality assessment of “naturally occurring” high-percentage L-dopa commercial products proposed as dietary supplements on the Internet: from labeling to analytical findings. Front Chem. 2025;13:1597784. PubMed.
  30. Phillips CR, Violi JP, Bishop DP, Rodgers KJ. Analysis of amino acids in Mucuna pruriens supplements using hydrophilic interaction liquid chromatography-tandem mass spectrometry. Amino Acids. 2026;58(1):6. PubMed.
  31. World Anti-Doping Agency. The 2026 Prohibited List. WADA.